Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Development Program to Engineer a New HPV Vaccine Initiated

Newsfile September 7, 2021

Defence Therapeutics Files Acid-Based Hydrogels USA Provisional Patent Application

Newsfile August 31, 2021

Defence Therapeutics (CSE:DTC) optimizes its ADC Therapeutic

Brieanna McCutcheon  August 18, 2021

Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic

Newsfile August 18, 2021

Defence Therapeutics Receives DTC Eligibility

Newsfile August 11, 2021

Defence Therapeutics Signs an Agreement with Biopharma Excellence, a Pharmalex GmbH Company, to Maximize and Strategize the Development of Its Accum(TM) Platform and Clinical Trials

Newsfile August 4, 2021

The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants

Newsfile July 6, 2021

Defence Therapeutics (CSE:DTC) signs collaboration agreement with the Curie Institute

John Ballem  June 29, 2021

Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer

Newsfile June 29, 2021

Defence Therapeutics’ (CSE:DTC) AccuTOX exhibits potent anti-cancer properties

John Ballem  June 22, 2021

Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties

Newsfile June 22, 2021

Defence Therapeutics (CSE:DTC) partners with the HUS Comprehensive Cancer Center

John Ballem  June 7, 2021

Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic

Newsfile June 7, 2021

RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

Newsfile June 1, 2021

Defence Therapeutics (CSE:DTC) advances pre-clinical testing of its infectious disease vaccine program

John Ballem  June 1, 2021

Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

Newsfile May 31, 2021

Top 5 Stories of the Week: Defence Therapeutics (CSE:DTC), Eloro Resources (TSXV:ELO), Kenorland Minerals (TSXV:KLD), HPQ Silicon (TSXV:HPQ), and Xigem Technologies (CSE:XIGM)

Julia Kennedy  May 28, 2021

Defence Therapeutics Inc. (CSE:DTC) completes AccuVAC-D001 cancer vaccine pre-clinical study

John Ballem  May 25, 2021

Defence Therapeutics AccuVAC-D001 Cancer Vaccine Generates Effective Long-lasting Anti-Tumoral Response

Newsfile May 25, 2021

Defence Therapeutics, Strong Therapeutics Pipeline: ADC's, Cancer and COVID Vaccines

Newsfile May 7, 2021